SteriPath Gen2 showing diverted contaminants

Steripath Gen2 Logo

Reduce blood culture contamination

Steripath® Gen2 Initial Specimen Diversion Device® (ISDD®) is supported by independent published clinical trial results over a 12-month period to sustain rates as low as 0.2% in the ED. With improved test results, patients can benefit from reduced risk of sepsis misdiagnoses and unnecessary antibiotic treatment.

A Contaminated Blood Culture

Blood culture collection remains the gold standard for diagnosing bloodstream infections and sepsis– the leading cause of death and readmission in US hospitals. Even with best practices, between 35-50% of positive blood culture results are contaminated, resulting in false-positive diagnoses that place over one million lives at risk each year.

Even current best practices are susceptible to:

Diagnosing Sepsis Human Factors

Human Factors

Risk of contamination during assembly and preparation of supplies, and skin prep

Diagnosing Sepsis Skin Flora

Skin Flora

You can disinfect but not sterilize the skin; up to 20% of skin flora remains viable in the keratin layer of the skin even after skin prep

Diagnosing Sepsis Skin Plugs

Skin Plugs

 Skin plugs, when present, will always enter the blood culture specimen bottle and commonly will contain microorganisms

Technology & Features

Steripath Gen2 Logo

Initial Specimen Diversion Mechanism
diverts and sequesters the initial (potentially contaminated) specimen into the isolation chamber


Specimen Isolation Chamber
ensures sequestered contaminants are isolated from the blood culture specimen


User-Controlled Diversion
enables necessary adjustments for “hard stick” patients with low venous pressure through negative pressure


Independent, Sterile Flow Path
completion of diversion automatically opens an independent flow path for specimen collection

Comes Preassembled & Sterile
to eliminate touch-point contamination

The Benefits

of accurate blood cultures

Reuce Patient Safety Risks

  • Reduce the risk of C. Diff & antibiotic-resistant infections by decreasing unecessary antibiotic usage
  • Reduce the risk of HAC/HAIs due to unnecessarily extended length of stay

Drive Antibiotic Stewardship

  • Reduce broad-spectrum antibiotic use
  • Supports compliance with federal and state mandates to reduce inappropriate antibiotic usage

Reduce Hospital Costs

Avoid non-reimbursable costs for:

  • Additional procedures, clinical coordination and length of stay
  • Unnecessary antibiotics, HAI/HAC events


Impact Quality Outcome Measures

  • Positively impact key CMS quality outcome metrics including reduced C. Diff. & HAI occurrences
  • Reduce false reporting for CLABSIs by significantly reducing false-positive blood culture test results

Steripath Gen2 is available in multiple configurations

Blood culture collection is possible through peripheral sticks and initial IV starts with available extensions.  It is also compatible with standard blood collection tubes and culture bottles made by BD, bioMerieux and certain Thermo Scientific products.

Available Extensions

21g Butterfly Needle
21g push button safety needle
23g Butterfly Needle
23g push button safety needle
Luer IV Extension Set
Luer IV Extension Set

Available Transfer Adapters

Thermo Scientific adaptor
Thermo Scientific adaptor
Smiths Adaptor
Smiths Adaptor
BD Adaptor
BD Adaptor

We’re with you, every step of the way

Our Clinical Partnership Includes:

• Pre-training and logistics including implementation planning meetings and online training

• Initial onsite implementation including train-the-trainer programs, sharing best practices, demonstrations, coaching, and training certifications

• Post-training resources including ongoing online training, onsite education, and retention modules

• Ongoing clinical support including tracking, reporting, compliance programs, root cause analysis, and clinical reviews

Money-Back Guarantee

If you do not achieve a 50% or greater sustained reduction in blood culture contamination, you get your money back.

Steripath is supported by independently published clinical trial results showing sustained blood culture contamination rates as low as 0.2% and a reduction in false positives by up to 92%.